1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Resistenz auf typ II JAK2 inhibition via persistente MAPK aktivierung kann durch MEK inhibition überwunden werden
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab-monotherapie ist eine wirksame und gut verträgliche behandlungsoption bei patienten mit rezidiviertem/refraktärem follikulärem lymphom, die zuvor bereits ≥2 therapielinien erhalten haben: Wichtige ergebnisse einer phase-I/II-studie
    Meeting Abstract

    Hess, G.; Budde, L. E.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Überlegenheit von axicabtagen ciloceucel als zweitlinientherapie bei großzelligem B-zell-lymphom mit ungünstigen, mit tumoraggressivität assoziierten prognostischen faktoren im vergleich zum therapiestandard (ZUMA-7)
    Meeting Abstract

    Dreger, P.; Locke, F.; Miklos, D.; Jacobson, C.; Perales, M. A.; Kersten, M. J.; Oluwole, O.; Ghobadi, A.; Rapoport, A.; McGuirk, J.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • 96-Wochen update aus der phase 3 ASCEMBL studie zur untersuchung von sicherheit und wirksamkeit von asciminib vs. bosutinib bei patienten mit chronischer myeloischer leukämie in chronischer phase nach vorbehandlung mit 2 TKI
    Meeting Abstract

    Hochhaus, A.; Réa, D.; Saussele, S.; Buske, S.; Balabanov, S.; Lang, F.; Sauer, T.; Gattermann, N.; Mauro, M.; Minami, Y.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Racial disparities in patients with TP53 mutated acute myeloid leukemia
    Meeting Abstract

    Badar, T.; Litzow, M. R.; Shallis, R.; Stahl, M.; Bewersdorf, J. P.; Saliba, A. N.; de Camargo Correia, G. S.; Patel, A. A.; Abaza, Y.; Murthy, G. S. G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Prognostic testing and treatment patterns in Black patients (pts) with chronic lymphocytic leukemia (CLL) from the informCLL prospective, observational registry
    Meeting Abstract

    Barrientos, J. C.; Mato, A.; Sharman, J. P.; Brander, D. M.; Gutierrez, M. E.; Wu, L.; Panjabi, S.; Young, A.; Upasani, S.; Naganuma, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Raising the level of cancer care: Feasibility and reported benefit of a virtual tumor board
    Meeting Abstract

    Chiec, L.; Dempsey, N.; Agarwal, M. S.; Ogden, J. R.; Broughman, J. R.; Mayo, Z.; Shonkwiler, E.; Chaby, M.; Socinski, M. A.; Pegram, M. D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the global phase 2 study TIDAL
    Meeting Abstract

    Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G. P.; López-Jiménez, J.; Reddy, N.; Mengarelli, A.; Phillips, T. J.; Musuraca, G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase II randomized study comparing proton craniospinal irradiation with photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis
    Meeting Abstract

    Yang, J. T.; Wijetunga, N. A.; Pentsova, E.; Wolden, S. L.; Young, R. J.; Correa, D.; Zhang, Z.; Zheng, J.; Warner, A. B.; Yu, H. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase I study of intravesical anti-CD40 agonist antibody 2141-V11 for non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin (BCG) therapy
    Meeting Abstract

    Wong, J. L.; Knorr, D.; Whiting, K.; Seshan, V. E.; Pietzak, E. J.; Donahue, T. F.; Cha, E. K.; Goh, A. C.; Smith, R.; Dalbagni, G.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save